These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 33326106)

  • 1. Ewing Sarcoma PDX Models.
    Surdez D; Landuzzi L; Scotlandi K; Manara MC
    Methods Mol Biol; 2021; 2226():223-242. PubMed ID: 33326106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor Growth Analysis of Ewing Sarcoma Cell Lines Using Subcutaneous Xenografts in Mice.
    Cidre-Aranaz F; Ohmura S
    Methods Mol Biol; 2021; 2226():191-199. PubMed ID: 33326103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of Wnt/β-Catenin in Ewing Sarcoma Cells Antagonizes EWS/ETS Function and Promotes Phenotypic Transition to More Metastatic Cell States.
    Pedersen EA; Menon R; Bailey KM; Thomas DG; Van Noord RA; Tran J; Wang H; Qu PP; Hoering A; Fearon ER; Chugh R; Lawlor ER
    Cancer Res; 2016 Sep; 76(17):5040-53. PubMed ID: 27364557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations.
    Nanni P; Landuzzi L; Manara MC; Righi A; Nicoletti G; Cristalli C; Pasello M; Parra A; Carrabotta M; Ferracin M; Palladini A; Ianzano ML; Giusti V; Ruzzi F; Magnani M; Donati DM; Picci P; Lollini PL; Scotlandi K
    Sci Rep; 2019 Aug; 9(1):12174. PubMed ID: 31434953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted imaging of Ewing sarcoma in preclinical models using a 64Cu-labeled anti-CD99 antibody.
    O'Neill AF; Dearling JL; Wang Y; Tupper T; Sun Y; Aster JC; Calicchio ML; Perez-Atayde AR; Packard AB; Kung AL
    Clin Cancer Res; 2014 Feb; 20(3):678-87. PubMed ID: 24218512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetically Engineered Mouse Model in Ewing Sarcoma.
    Tanaka M; Nakamura T
    Methods Mol Biol; 2021; 2226():183-189. PubMed ID: 33326102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orthotopic Implants in Mice.
    Stewart E
    Methods Mol Biol; 2021; 2226():215-222. PubMed ID: 33326105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a preclinical orthotopic xenograft model of ewing sarcoma and other human malignant bone disease using advanced in vivo imaging.
    Vormoor B; Knizia HK; Batey MA; Almeida GS; Wilson I; Dildey P; Sharma A; Blair H; Hide IG; Heidenreich O; Vormoor J; Maxwell RJ; Bacon CM
    PLoS One; 2014; 9(1):e85128. PubMed ID: 24409320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metastasis Assessment in Ewing Sarcoma Using Orthotopic Xenografts.
    López-Alemany R; Tirado OM
    Methods Mol Biol; 2021; 2226():201-213. PubMed ID: 33326104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The histone demethylase KDM3A, and its downstream target MCAM, promote Ewing Sarcoma cell migration and metastasis.
    Sechler M; Parrish JK; Birks DK; Jedlicka P
    Oncogene; 2017 Jul; 36(29):4150-4160. PubMed ID: 28319067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reactivation of TWIST1 contributes to Ewing sarcoma metastasis.
    Choo S; Wang P; Newbury R; Roberts W; Yang J
    Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28873262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using Zebrafish Larvae as a Xenotransplantation Model to Study Ewing Sarcoma.
    Pascoal S; Grissenberger S; Scheuringer E; Fior R; Ferreira MG; Distel M
    Methods Mol Biol; 2021; 2226():243-255. PubMed ID: 33326107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ewing sarcoma dissemination and response to T-cell therapy in mice assessed by whole-body magnetic resonance imaging.
    Liebsch L; Kailayangiri S; Beck L; Altvater B; Koch R; Dierkes C; Hotfilder M; Nagelmann N; Faber C; Kooijman H; Ring J; Vieth V; Rossig C
    Br J Cancer; 2013 Aug; 109(3):658-66. PubMed ID: 23839490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
    Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
    Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma.
    Cidre-Aranaz F; Grünewald TG; Surdez D; García-García L; Carlos Lázaro J; Kirchner T; González-González L; Sastre A; García-Miguel P; López-Pérez SE; Monzón S; Delattre O; Alonso J
    Oncogene; 2017 Feb; 36(6):766-776. PubMed ID: 27375017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of patient-derived xenograft engraftment in pediatric sarcomas.
    Castillo-Ecija H; Pascual-Pasto G; Perez-Jaume S; Resa-Pares C; Vila-Ubach M; Monterrubio C; Jimenez-Cabaco A; Baulenas-Farres M; Muñoz-Aznar O; Salvador N; Cuadrado-Vilanova M; Olaciregui NG; Balaguer-Lluna L; Burgueño V; Vicario FJ; Manzanares A; Castañeda A; Santa-Maria V; Cruz O; Celis V; Morales La Madrid A; Garraus M; Gorostegui M; Vancells M; Carrasco R; Krauel L; Torner F; Suñol M; Lavarino C; Mora J; Carcaboso AM
    J Pathol Clin Res; 2021 Jul; 7(4):338-349. PubMed ID: 33837665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of clinically relevant in vivo metastasis models using human bone discs and breast cancer patient-derived xenografts.
    Lefley D; Howard F; Arshad F; Bradbury S; Brown H; Tulotta C; Eyre R; Alférez D; Wilkinson JM; Holen I; Clarke RB; Ottewell P
    Breast Cancer Res; 2019 Nov; 21(1):130. PubMed ID: 31783893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The second European interdisciplinary Ewing sarcoma research summit--A joint effort to deconstructing the multiple layers of a complex disease.
    Kovar H; Amatruda J; Brunet E; Burdach S; Cidre-Aranaz F; de Alava E; Dirksen U; van der Ent W; Grohar P; Grünewald TG; Helman L; Houghton P; Iljin K; Korsching E; Ladanyi M; Lawlor E; Lessnick S; Ludwig J; Meltzer P; Metzler M; Mora J; Moriggl R; Nakamura T; Papamarkou T; Radic Sarikas B; Rédini F; Richter GH; Rossig C; Schadler K; Schäfer BW; Scotlandi K; Sheffield NC; Shelat A; Snaar-Jagalska E; Sorensen P; Stegmaier K; Stewart E; Sweet-Cordero A; Szuhai K; Tirado OM; Tirode F; Toretsky J; Tsafou K; Üren A; Zinovyev A; Delattre O
    Oncotarget; 2016 Feb; 7(8):8613-24. PubMed ID: 26802024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the IGF1R/PI3K/AKT Pathway Sensitizes Ewing Sarcoma to BET Bromodomain Inhibitors.
    Loganathan SN; Tang N; Holler AE; Wang N; Wang J
    Mol Cancer Ther; 2019 May; 18(5):929-936. PubMed ID: 30926641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highly personalized detection of minimal Ewing sarcoma disease burden from plasma tumor DNA.
    Hayashi M; Chu D; Meyer CF; Llosa NJ; McCarty G; Morris CD; Levin AS; Wolinsky JP; Albert CM; Steppan DA; Park BH; Loeb DM
    Cancer; 2016 Oct; 122(19):3015-23. PubMed ID: 27351911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.